알림

알림 Pro 차트

Cardiff Oncology Inc. (CRDF)

NasdaqCM: CRDF · 실시간 가격 · USD

0.98

-0.01 (-1.01%)

종가 기준: Aug 13, 2026, 3:59 PM

1.02

+3.66%

애프터마켓: 7:34 PM

-1.01% (1D)

매수호가	0.98
시가총액	76.55M
매출 (ttm)	508K
순이익 (ttm)	-40.08M
베타	n/a
EPS (ttm)	-0.6
P/E (ttm)	n/a
선행 P/E	-1.57
P/B (ttm)	1.94
P/S (ttm)	150.69
Earnings Date	Nov 12, 2026

매도호가	1.28
거래량	599,240
평균 거래량 (20일)	1,572,011
시가	0.99
전일 종가	0.99
일중 범위	0.97 - 1.06
52주 범위	0.76 - 3.31
애널리스트	Buy
목표주가	4 (308.16%)
배당	n/a
배당락일	n/a

CRDF 소개

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Jul 27, 2004

직원 수 30

상장 거래소 NasdaqCM

티커 CRDF

웹사이트 https://www.cardiffoncology.com

전체 기업 정보

재무 실적

2025년 Cardiff Oncology의 매출은 593K로, 전년 683K 대비 -13.18% 감소했습니다. 순이익은 -45.85M로, 0.92% 증가했습니다.

재무제표

애널리스트 전망

애널리스트 7명의 투자의견을 종합하면 CRDF 주식의 평균 등급은 "Buy"입니다. 12개월 목표주가는 4로, 최근 주가 대비 308.16% 상승 여력입니다.

주가 전망

어닝 서프라이즈

Cardiff Oncology가 Aug 11, 2026에 분기 실적을 발표했습니다:

매출 $41K 예상치 하회 $0, 및 -62.39% 전년 대비 감소.

EPS -0.14 예상치 상회 0.02, 및 33.33% 전년 대비 성장.

다음 실적 발표

Cardiff Oncology Inc.의 실적 발표 예정일은 Nov 12, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

4주 전 · InvestorsHub

Cardiff Oncology Announces $10 Million Registered Direct Offering to Strengthen Working Capital

Cardiff Oncology has secured a $10 million registered direct offering, providing additional capital for working capital and general corporate purposes as the company continues advancing its lead oncol...

1개월 전 · Insider Monkey

Is Cardiff Oncology, Inc. (CRDF) Stock Undervalued Amid Legal Uncertainty and Future Cancer Drug Potential?

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. Cardiff Oncology, Inc. (NASDAQ:CRDF) is one of the most promising stocks on our list. TheFly repor...

2개월 전 · Simply Wall St.

Cardiff Oncology And 2 Other Promising Penny Stocks For Your Watchlist

Over the last 7 days, the U.S. market has dropped by 1.0%, yet it has risen by 23% over the past year, with earnings forecasted to grow annually by 17%. In such a fluctuating market, identifying stock...

4개월 전 · MarketBeat

Cardiff Oncology Showcases Onvansertib: 72% ORR Signal in Phase II RAS-Mutant mCRC Webinar

Cardiff Oncology (NASDAQ:CRDF) interim CEO Mani Mohindru outlined updated clinical results and development plans for the company’s investigational PLK1 inhibitor onvansertib during a webinar focused o...

5개월 전 · MarketBeat

Cardiff Oncology Spotlights Onvansertib Data at Oppenheimer: 72% ORR in RAS-Mutant mCRC

Cardiff Oncology (NASDAQ:CRDF) used an appearance at Oppenheimer’s 36th Annual Healthcare Conference to highlight updated clinical results and its development plans for onvansertib, an oral, highly se...

2 페이지 중 1

Cardiff Oncology Inc. (CRDF)